Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC trimmed its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 6.6% during the first quarter, Holdings Channel reports. The institutional investor owned 332,900 shares of the company’s stock after selling 23,700 shares during the period. Gabelli Funds LLC’s holdings in Teva Pharmaceutical Industries were worth $10,027,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in TEVA. Legal & General Group Plc grew its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 4th quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after buying an additional 228,189 shares during the period. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $1,098,060,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Teva Pharmaceutical Industries by 8.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock valued at $33,506,000 after acquiring an additional 80,106 shares in the last quarter. TD Asset Management Inc grew its holdings in Teva Pharmaceutical Industries by 47.1% during the 4th quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after purchasing an additional 118,075 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at about $9,126,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $30.78 on Monday. The company has a 50-day moving average of $33.29 and a 200-day moving average of $32.69. The firm has a market cap of $35.40 billion, a price-to-earnings ratio of 23.15, a price-to-earnings-growth ratio of 3.25 and a beta of 0.86. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $3.98 billion for the quarter. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.99 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the transaction, the executive vice president owned 172,184 shares of the company’s stock, valued at approximately $6,131,472.24. This represents a 47.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. This trade represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 465,931 shares of company stock valued at $16,332,989 in the last three months. Insiders own 0.54% of the company’s stock.

Analysts Set New Price Targets

TEVA has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Friday, July 17th. UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday, April 30th. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.78.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.